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*A companion article titled “Fun-
gal Infections of the Upper Res-
piratory Tract” appeared in the
May 2008 issue and is available
online at compendiumequine.com.
ystemic fungal infections can have an
insidious progression, often presenting with
nonspecific clinical signs. A thorough clini-
cal evaluation is usually required to confirm the
diagnosis. Historically, fungal disease has been
associated with a poor prognosis in horses and
other species. However, with earlier diagnosis
and the increasing availability of affordable anti-
fungals with known pharmacokinetic profiles,
guarded prognoses and successful outcomes are
likely to be more common in
horses with fungal infections.
FUNGI
There are more than 70,000 species of fungi,
but only 50 species have been identified as
causes of disease in people or animals. Fungi are
eukaryotic organisms with a definitive cell wall
made up of chitins, glucans, and mannans.
Within the cell wall, the plasma membrane
contains ergosterol—a cell membrane sterol
that is frequently targeted by antifungal agents. 
CLINICAL SIGNS AND 
GROSS LESIONS
Patients with pulmonary infections that
cause pulmonary granulomas, diffuse pneumo-
nia, or pleuropneumonia can present with signs
similar to those of bacterial infection. Signs
may include coughing, nasal discharge, tachyp-
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ABSTRACT: Pulmonary or systemic fungal infections in horses are associated with a high mortality
rate. The diagnosis can be difficult; the clinical signs depend on the extent of organ dysfunction. 
For pulmonary infections, thoracic radiography and collection of fluid samples by tracheal wash 
or bronchoalveolar lavage are useful. Biopsy samples may be obtained percutaneously or during
laparoscopy/thoracoscopy or laparotomy/thoracotomy. Cytologic or histologic examination of
lesions may identify characteristic morphologic features of fungal organisms. The etiologic agent 
can be definitively identified by microbiologic culture, immunohistochemistry, or polymerase chain
reaction. Serologic titers can provide a noninvasive presumptive diagnosis for many conditions.
Candidemia has been diagnosed by blood and urine cultures. Assessment of immune function is
warranted to identify possible immunodeficiencies before long-term treatment. Although mortality
rates are high, there have been some recent successful outcomes after treatment with amphotericin
B, itraconazole, or fluconazole. 
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nea, respiratory distress, and, if the
condition is chronic, weight loss.
Fungal pneumonia sometimes
affects horses that are immunocom-
promised or neutropenic or that
have enteritis/colitis, bacterial pneu-
monia, or neoplasia. Systemic infec-
tions can have variable clinical signs
depending on the location and
extent of the infection. Fungal
infections can affect multiple organ
systems and body cavities. Weight
loss, colic, and diarrhea often occur
with infection within the abdominal
cavity. Immunodeficiency, either
congenital or acquired, or glucocor-
ticoid therapy may predispose a
horse to fungal infection.
DIAGNOSTIC
DIFFERENTIALS
Diagnostic differentials for a pul-
monary or thoracic mass include bac-
terial abscess, neoplastic mass, and
granulomatous mass. The radi-
ographic appearance of fungal pneu-
monia can be variable, although a
miliary or diffuse alveolar pattern is
frequently observed. Differentials
include bacterial pneumonia, recur-
rent airway obstructive disease, silico-
sis, granulomatous disease complex,
and neoplasia.
DIAGNOSIS 
Diagnostic Samples
Masses in the mediastinum or
lungs may be observed radiographi-
cally. Ultrasonographic imaging may
detect pleural or peritoneal fluid
that can be aspirated or parenchy-
mal abnormalities, f rom which
biopsy samples can be obtained per-
cutaneously. Fungal pneumonia may
be diagnosed from samples obtained
from tracheal wash or bronchoalve-
olar lavage fluid or f rom a lung
biopsy (Figure 1). Lung biopsy is
associated with significant risk
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because a pulmonary vessel may accidentally be dissected. The biopsy
should be performed with ultrasound guidance and obtained from the
periphery of the lung. (Some horses have experienced fatal hemorrhage
associated with biopsy of a vessel only 2 cm from the periphery.) The lungs
are rich in plasminogen, so bleeding complications may be severe. Spring-
loaded biopsy needles are suitable for lung biopsy. Cytologic or biopsy sam-
ples from other organs may be obtained during exploratory laparoscopy,
thoracoscopy, laparotomy, or thoracotomy.
Cytology
Fungal hyphae may be identified in airway, peritoneal, or pleural fluid or
in impression smears obtained from biopsy samples of masses. Some fungi
can be found in tracheal aspirates from healthy horses (Figure 2). Barn
fungi such as Alternaria spp are nonpathogenic and rarely incite an inflam-
matory response in the host. The organisms often have a block-like appear-
ance and may be colored. A normal predominance of macro phages and
lymphocytes as well as less than 10% nondegenerate neutrophils would be
expected. With fungal pneumonia, the aspirate may contain intracellular
fungal hyphae and predominately neutrophils that are often degenerate. If
processing of the sample is delayed, extracellular fungi may be phagocy-
tized, which confuses the interpretation. Some fungi have characteristic
morphologic features that can lead to an early presumptive identification. 
Histopathology
Hyphae of certain fungi may be poorly visualized using routine hema-
toxylin–eosin stain; therefore, special stains (e.g., periodic acid-Schiff, Grid-
ley’s fungus, Grocott–Gomori methenamine–silver nitrate) can be useful in
identifying histopathologic specimens. With chronic infection, there is often
evidence of extensive fibrosis.
Microbiologic Culture
Some fungi that have fastidious growth requirements may be overgrown by
contaminant bacteria and may take up to several weeks to grow on culture
media. To transport tissue for microbiologic culture, the sample should be
placed in a prepared culture media and transported at room temperature. Spe-
cific culture media such as Sabouraud’s dextrose agar, inhibitory mold agar, or
mycobiotic agar containing cycloheximide and chloramphenicol are useful. 
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Systemic fungal disease is rare in horses. Reported infections
include blastomycosis, histoplasmosis, aspergillosis,
coccidioidomycosis, candidiasis, pneumocystosis, and
cryptococcosis. Pulmonary infections caused by Scopulariopsis
spp and adiaspiromycosis have also been reported.
Molecular Techniques
Serologic tests that use immunodiffusion,1 radioim-
munoassays, complement fixation, or ELISAs2 are avail-
able to detect circulating antibodies against several
fungal organisms (Cryptococcus neoformans,3–5 Coccidioides
immitis,6,7 Blastomyces dermatitidis,8 Aspergillus spp,9
Histoplasma capsulatum).1 These tests can also help mon-
itor response to treatment. Titers often decrease with
resolution of disease. Immunohistochemistry,10–13 fluo-
rescent in situ hybridization,12 and DNA probes8 can be
used to diagnose fungal organisms in histopathology
sections.
IMMUNE-FUNCTION TESTING
Several fungal infections have been associated with
host immune suppression caused by severe malnutrition,
congenital immunodeficiency, or acquired immuno -
deficiency.14–16 Blood can be tested for immuno globulin
quantification by radial immunodiffusion and lympho-
cyte subpopulation phenotyping via flow cytometry.16,17
ANTIFUNGAL THERAPEUTICS
Antifungals used in horses have been reviewed.18
Amphotericin B is one of the most efficacious antifun-
gals, but its use is limited because of the risk of
nephrotoxicity. Benzimidazole derivatives from the
azole class that can be administered systemically
include ketoconazole, itraconazole, fluconazole, and
voriconazole. They destroy fungi by inhibition of
ergosterol biosynthesis in the fungal cell membrane
(Table 1).
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Figure 1. Percutaneous lung biopsy from the caudal
periphery of the lung.
Figure 2. Alternaria spp from transtracheal wash
specimens obtained from healthy horses. (Modified Wright’s
stain; bars = 50 μm)
An extracellular spore (arrow) with several macrophages and a
squamous cell (indicative of pharyngeal contamination).
Extracellular hyphae (arrow). 
An intracellular spore (arrow) within a binucleated macrophage.
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FUNGAL INFECTIONS
Cryptococcosis
Cryptococcosis is commonly caused by C. neoformans
(var neoformans, var grubii, var gattii), a ubiquitous, sapro-
phytic, round, basidiomycetous yeast-like fungus (5 to 10
µm) with a large heteropolysaccharide capsule (1 to 30
µm) that does not take up common cytologic stains (Fig-
ure 3). The capsule forms a clear halo when stained with
India ink. The capsule is immunosuppressive and
antiphagocytic. Capsular antigens that are secreted into
the host’s body fluids bind opsonizing antibody before it
reaches the organism. Equine cryptococcosis is relatively
common in Western Australia,3 and there is an epidemi-
ologic relationship between C. neoformans var gattii and
the Australian river red gum tree (Eucalyptus camaldulen-
sis) and between C. neoformans var neoformans and bird
(particularly pigeon) excreta.3 Cytologic or histopatho-
logic identification is very reliable for diagnosis because
of the characteristic morphology. Serologic testing with
latex agglutination to identify cryptococcal capsular anti-
gen is useful (92% sensitivity and 98% specificity in small
animals5), and resolution of lesions is correlated with
declining serum titers.4
Cryptococcosis in horses is associated primarily with
pneumonia, rhinitis, meningitis, and abortion. However,
successful medical treatment has rarely been reported.
Surgical removal of a localized jejunal lesion was success-
ful in one horse.19 A pony with multiple pulmonary
cryptococcomas, from which Cryptococcus neoformans var
gattii was cultured from transtracheal washings and lung
mass aspirate, was treated successfully with daily infu-
sions of amphotericin B for 1 month. One year after ces-
Table 1. Systemic Antifungals Used to Treat Horses
Drug Dosage
Successfully Treated 
Conditions in Horses Comments
Amphotericin B 0.3 mg/kg in 1 L 5% dextrose, increasing
every 3 days by 0.1 mg/kg until a dose of 
0.9 mg/kg IV infusion is given for 30 daysa
Histoplasmosis29
Pulmonary cryptococcosis4
Pulmonary aspergillosis2
Nephrotoxic: consider diuresis
with intravenous fluids.
Phlebitis: use a catheter.
Ketoconazole 30 mg/kg via nasogastric tube q12h mixed
with 0.2 normal hydrochloric acid40
Scopulariopsis pneumonia40 Low oral bioavailability in
the nonacidified form.39
Itraconazole
(Sporanox
solution)
5 mg/kg PO q24h27 Coccidioides immitis
infection37
Compounding is not
recommended. 
Fluconazole Loading dose of 14 mg/kg followed by 5
mg/kg q24h38
Anecdotal reports of successful treatment 
of fungal keratitis using 1 mg/kg PO q24h 
C. immitis infection34
Candida bacteremia42
Minimal activity against
filamentous fungi (Aspergillus
and Fusarium spp.). 
Compounded fluconazole
formulations are very stable.
Voriconazole 3 mg/kg PO q12h25
4 mg/kg PO q24h26
Blastomyces dermatitidis
infection 
C. immitis infection
Histoplasma capsulatum
infection 
Candida infection 
Aspergillus infection 
Potent in vitro activity against
B. dermatitidis, C. immitis, 
and H. capsulatum. 
Good activity against
Candida and Aspergillus spp.
One of the safest antifungals
used in humans.
Enilconazole 1.2 mg/kg aerosolized q12h in 125 mL 
of saline (extrapolated dose)40
Part of the successful
treatment of Scopulariopsis
pneumonia40
Not commercially available
in the United States.
aChaffin MK, Schumacher J, McMullan WC. Cutaneous pythiosis in the horse. Vet Clin North Am Equine Pract 1995;11:91-103.
sation of treatment, clinical signs had resolved and the
cryptococcal antigen titer decreased from 4096 to 256.4
Aspergillosis
Aspergillosis in horses has been reviewed.20,21 Aspergillus
spp have broad (2 to 4 µm in diameter), septate hyphae
with parallel sides and acute right-angled branching.
They have a propensity for vascular invasion. A defini-
tive diagnosis can be made by culture or staining by
immunohistochemistry or immunofluorescence (Fusar-
ium spp and Pseudallescheria boydii look similar on histo-
logic examination).10,13 Aspergillus spp are very common
in the environment, especially in moldy feed and bed-
ding.2 They are opportunistic pathogens and often cause
disease in horses that are immunosuppressed f rom
debilitating conditions (e.g., enterocolitis, septicemia,
neoplasia, Cushing’s disease, equine protozoal myeloen-
cephalitis) or major surgery or that have been treated
with immunosuppressive drugs10,20–23 (Figure 4). 
Infection is by inhalation of an overwhelming number
of spores or by translocation of organisms across an
inflamed gastrointestinal tract. Aspergillus pneumonia is
almost uniformly fatal, often with no or mild respiratory
signs. The two forms of Aspergillus pneumonia probably
reflect the two portals of entry, with fungal proliferation
and invasion of the small airways occurring secondary to
inhalation, and angioinvasive aspergillosis with lesions
centered around large blood vessels likely due to
hematogenous infection originating from the gastroin-
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Figure 3. Transtracheal wash specimen from a horse.
Cryptococcus neoformans with its characteristic wide, nonstaining
capsules and narrow-based budding (arrow). (Modified Wright’s
stain; bar = 60 μm) 
A dyspneic foal being supported with intranasal
oxygen. The foal had more than eight septic
joints and severe pneumonia and was
subsequently euthanized because of a guarded
prognosis. 
Aspergillus hyphae within the pulmonary
parenchyma. (Stained metachromatic with
Gridley stain; bar = 30 μm; courtesy of
Calvin Johnson, Auburn University)
A photomicrograph of the pleural surface of
the lung (arrows) with extensive superficial
and deep fungal growth. Aspergillus spp
characteristically have parallel-sided, regular
septate hyphae with acute-angled
dichotomous branching. They are seen
reasonably well with hematoxylin–eosin
stain. (bar = 60 μm) 
Figure 4. A 1-month-old foal with Escherichia coli septicemia and secondary Aspergillus pneumonia. 
testinal tract. In two retrospective studies of invasive
pulmonary aspergillosis, 41 of 49 cases were associated
with enterocolitis.21,22
Pulmonary aspergillosis is characterized grossly by
multiple nodules throughout the lungs. On histologic
examination, there is often necrosis and purulent
inflammation. Necrosis is due to toxin and enzyme pro-
duction as well as vascular obstruction. Fungal invasion
of blood vessels is common and results in vasculitis,
thrombosis, infarction, and necrosis. Chronic lesions are
granulomatous, with macrophages, neutrophils, and
multinucleated giant cells predominating. 
Antemortem diagnosis of pulmonary aspergillosis is
rare. In a retrospective study of 30 cases of Aspergillus
pneumonia, only two cases were diagnosed or suspected
antemortem.21 Transtracheal aspirate or bronchoalveolar
lavage may not be helpful because hyphae and spores are
often present extracellularly or within macrophages in
aspirate and lavage from healthy animals.22 False-nega-
tive results can also occur. Two days before euthanasia,
cytologic examination of a transtracheal wash specimen
obtained from the foal in Figure 4 failed to identify
Aspergillus hyphae. Serologic diagnosis has occasionally
been useful9 but is often unreliable. Development of a
commercial ELISA is promising.2,20
Fifty percent to 90% of humans with invasive asper -
gillosis die despite treatment. For decades, amphotericin
B has been the mainstay of treatment of invasive infec-
tion with Aspergillus but is associated with nephrotoxic-
ity in about 50% of patients. Nephrotoxicity is reduced
using liposomal amphotericin B. Amphotericin B col-
loidal dispersion is not recommended because of the risk
of infusional toxicities.24
Voriconazole, a new azole antifungal, is now consid-
ered the drug of choice in treating human aspergillosis,
while caspofungin (in the new class echinocandin anti-
fungals) shows promising results in patients with refrac-
tory infections.24 The pharmacokinetics of voriconazole
have recently been determined in horses, with excellent
absorption after oral administration and high concentra-
tions achieved in several body fluids.25,26 Voriconazole 
is still prohibitively expensive; therefore, oral itraconazole
is currently preferred for treating aspergillosis in horses.27
In humans, the use of itraconazole has shown response
rates comparable to those associated with the use of
amphotericin B.24 There is a limited number of reports of
horses surviving pulmonary aspergillosis. One horse with
Aspergillus pneumonia survived with amphotericin B
therapy (the dose and duration were not reported).2
Blastomycosis 
Blastomycosis is caused by inhalation of conidia of the
thermally dimorphic saprophytic fungus B. dermatitidis.
Blastomyces yeasts can be identified on cytologic exami-
nation, often within multinucleated giant cells. They are
spherical and 15 to 17 µm in diameter with basophilic
protoplasm and unstained, uniformly shaped refractile
walls. Unilateral, broad-based budding is characteristic. 
Blastomycosis reportedly caused pulmonary abscessa-
tion, pyogranulomatous pneumonia, pleuritis, peritoni-
tis, and abscesses in a 5-year-old horse.8 B. dermatitidis
was positively identified from transtracheal wash fluid
by use of a DNA probe, and serology was strongly posi-
tive. Treatment was declined, and the horse was eutha-
nized.8 Disseminated blastomycosis was diagnosed in a
miniature horse with subcutaneous infections associated
with a chronic pectoral wound. The horse had pleural
effusion and pulmonary consolidation. Yeasts were
observed by histologic examination in many tissues, and
B. dermatitidis was cultured after 6 weeks.28
Histoplasmosis
Histoplasmosis is caused by the saprophytic, dimor-
phic fungus H. capsulatum and is most prevalent in
moist soil containing bird or bat waste. Yeast organisms
are 2 to 4 µm in diameter with a thin, clear halo sur-
rounding a round or crescent-shaped basophilic cyto-
plasm (Figure 5). H. capsulatum may occur in an enteric,
a pulmonary, or a disseminated form29 (Figure 6). Histo-
plasmosis has been reported infrequently in horses29;
thus horses are considered to be relatively resistant to
the disease. H. capsulatum was identified in pulmonary
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Clinical signs of systemic fungal infection may include fever, weight loss,
sudden death, respiratory signs (e.g., nasal discharge, coughing, respiratory distress),
or gastrointestinal signs (e.g., diarrhea, colic). 
granulomas in a horse dying of chronic Yersinia colitis30
and in another horse with intestinal salmonellosis.31 It
has also been associated with abortions and severe gran-
ulomatous pneumonia in neonatal foals and a yearling.1
Successful treatment with amphotericin B was reported
in a filly with pulmonary histoplasmosis diagnosed by
cytologic identification of the organism from lung aspi-
rate and a tracheal wash smear. The filly was treated with
increasing doses of amphotericin B over a 4-week period.
After every treatment, the filly became extremely lethar-
gic for 18 to 24 hours. In the 4th week of therapy, there
was transient polyuria and polydipsia; however, there was
no azotemia or loss in urine-concentrating ability.29
Coccidioidomycosis
Coccidioidomycosis is a systemic fungal infection
caused by C. immitis—a soil saprophyte that grows in
areas with sandy, alkaline soils and semiarid conditions.6
In the environment, C. immitis exists as a mycelium with
thick-walled, barrel-shaped arthroconidia. Inhalation of
airborne arthroconidia can result in infection. Inhaled
arthroconidia can enlarge to form nonbudding spherules,
which incite an inflammatory reaction in the lungs and
lymph nodes.6 Affected horses can experience weight
loss, fever, abdominal pain, and signs of respiratory dis-
ease. Localized, recurring nasal granulomas have also
been reported.32 Diffuse infections with granulomas in
the lungs, liver, kidneys, or spleen have a grave progno-
sis.6 Przewalski’s horses may be more susceptible.33
C. immitis is difficult to culture, and spherules may
not be observed histologically from antemortem lung
biopsies. However, serology is very useful to diagnose
infection, and decreasing titers are associated with clini-
cal improvement.6,34 Serum antibodies are rarely
detected in healthy horses.7 Antifungals that have been
used successfully to treat infected dogs include keto-
conazole, fluconazole, and itraconazole.35 A very low
dose of unacidified ketoconazole (3 to 6 mg/kg/day PO)
did not achieve serum concentrations above the minimal
inhibitory concentration and was unsuccessful in treat-
ing several cases of coccidioidomycosis in horses.6,36 Itra-
conazole (2.6 mg/kg PO q12h) was effective in treating
coccidioidomycotic vertebral osteomyelitis in a foal.37
Fluconazole administered at the recommended dosage38
for 5 to 6 months was successful in treating two geld-
ings with pulmonary coccidioidomycosis.34 Oral therapy
with acidified ketoconazole39 at recommended dosages
or with itraconazole could be considered in future cases. 
Scopulariopsis 
In a 2-year-old quarter horse filly, Scopulariopsis pneu-
monia was diagnosed by culture of bronchoalveolar
lavage fluid. The filly had extensive granulomatous
lesions within the pulmonary parenchyma and pleural
effusion visible on thoracic ultrasonography. The infec-
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Figure 6. Disseminated histoplasmosis was diagnosed in
an 11-year-old quarter horse stallion that presented with
severe weight loss. Histoplasma organisms were observed on the
peripheral blood smear. Severe respiratory distress developed, and
thoracic radiographs showed a coalescing alveolar pattern around
the hilar region, with air-filled cavitary lesions in the caudodorsal
lung fields. The disease progressed rapidly, and the stallion was
euthanized. (Courtesy of Peggy Marsh, Texas A&M University)
Figure 5. A photomicrograph of small intestinal
submucosa infiltrated by activated macrophages, many of
which contain multiple Histoplasma yeasts. These yeasts
characteristically measure approximately 2 to 4 μm and appear with
a basophilic center and clear halo. (Hematoxylin–eosin stain; bar = 30
μm; Courtesy of Arno Wünschmann, University of Minnesota)
tion resolved following multimodal therapy with keto-
conazole for 9 days, which was discontinued because of
expense and replaced with aerosolization of enilconazole
for 23 days.40
Adiaspiromycosis
A horse was diagnosed by percutaneous lung biopsy
with adiaspiromycosis miliary fungal pneumonia caused
by the saprophytic soil mold Emmonsia crescens. No treat-
ment was attempted, and the horse was euthanized.41
Candidiasis
Systemic candidiasis was diagnosed and successfully
treated in four neonatal foals. Each foal had prior sep-
sis attributable to gram-negative bacteria that had
been aggressively treated with numerous antibiotics
and parenteral nutrition. Candida albicans was cul-
tured from a transtracheal wash from one of the foals.
Three of the foals had Candida glossitis, and one had
panophthalmitis and fungal keratitis. Two of the foals
were treated with intravenous amphotericin B for 8
days (total dose: 2.6 mg/kg) and 29 days (total dose:
10.3 mg/kg), respectively. Fluconazole (5.5 mg/kg PO
q24h for 6 weeks and 4 mg/kg PO q24h for 28 days)
was used to treat the other two foals.42 Superficial
Candida infections of the mucous membranes (thrush)43
can occur in isolation or as part of a systemic infec-
tion, and further microbiologic culturing of the blood,
tracheal wash fluid, urine, or joint fluid may be indicated
to rule out systemic infection.42 Candida gloss itis can be
treated by rinsing the mouth with either potassium per-
manganate (0.025% q24h) or nystatin (0.3 g in 10 mL
of water q8h). 
Candidemia is the most frequent fungal infection in
humans who undergo complex abdominal surgery,
receive total parenteral nutrition, are neutropenic with
malignancies, have been burned, or receive long-term
corticosteroid therapy. Candida spp account for 8% to
10% of all blood culture isolates and rank fourth among
the most frequently isolated pathogens in blood cultures
from humans.24 The mortality rate of patients with can-
didemia is 40% to 75%.24 More than 60% of isolates are
C. albicans.24 Fluconazole is generally considered the
preferred drug in treating Candida infection, although
Candida krusei is resistant to fluconazole. Itraconazole,
amphotericin B, caspofungin, and voriconazole are alter-
native antifungals recommended in humans.24
Pneumocystosis
Pneumocystis carinii has been reclassified from a proto-
zoan to a saprophytic fungus based on the DNA
sequence of its 16S-like RNA subunit. Some researchers
even consider it a plant because it lacks ergosterol, the
major fungal sterol.44 P. carinii exists in two parasitic
forms. The yeast form (trophozoite) is ameboid and 2 to
5 µm in diameter with filopodia that attach to the sur-
face of type I pneumocytes. The sporangia (cystic form)
are 4 to 6 µm in diameter and contain eight uninucleate
spores (intracystic bodies). The yeast cell stains well with
hematoxylin–eosin stain, while sporangia can be identi-
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Therapy must often be administered long term.
It is expensive and carries only a fair to guarded prognosis.
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fied with Grocott–Gomori methenamine–silver nitrate
and periodic acid-Schiff stains. P. carinii cannot be cul-
tured, and diagnosis of P. carinii infection is based on the
identification of characteristic morphologic features. A
fluorescent in situ hybridization method with an
oligonucleotide probe that targets the 18S ribosomal
RNA has been developed to detect P. carinii in histologic
sections.12 Immunohistochemistry can also be used.11
P. carinii infection causes diffuse interstitial pneumonia,
especially in immunocompromised patients such as Ara-
bian foals with severe combined immunodeficiency.14 It
has also been diagnosed in immuno-
compromised adult horses15,16 and in
an immunocompetent foal.11 Three-
quarters of humans with AIDS are
infected with P. carinii, and people
undergoing immunosuppressive ther-
apy after organ transplantation are
predisposed. P. carinii infection is best
diagnosed by cytology using speci-
mens obtained from bronchoalveolar
lavage rather than tracheal wash.
Trimethoprim–sulfamethoxazole (25
to 30 mg/kg PO q12h) is the treat-
ment of choice.45 Dapsone (3 mg/
kg/day PO for 2 months) was used to
successfully treat a foal with P. carinii
infection that developed Salmonella
enterocolitis after treatment with
trimethoprim–sulfamethoxazole.17
Pythiosis
Pythium insidiosum is a fungus-like
aquatic organism in the kingdom
Stramenopila and phylum Oomycota
that affects mammalian species living
in tropical and subtropical climates.
Pythiosis is generally associated with
large, ulcerative, proliferative, pyo-
granulomatous lesions that affect
cutaneous and subcutaneous tissues
of the extremities, ventral abdomen,
and face. However, infection can dis-
seminate to the intestines, bones,
arteries, lungs, liver, and spleen.46–49 P.
insidiosum lesions are characterized
by the presence of sparsely septate
hyphae within eosinophilic granulo-
matous lesions. The hyphae resemble
those of fungi in the class Zygomycetes (Conidiobolus
and Basidiobolus spp), but P. insidiosum does not have
ergosterol in its cell membrane and is, therefore, not a
true fungus. This explains why most antifungals are gen-
erally ineffective at treating pythiosis.47 There is one
report of successful treatment of periorbital pythiosis in
a child by using a combination of terbinafine and itra-
conazole for 1 year,50 and there are anecdotal reports
that this drug combination was successful in treating
20% to 25% of canine pythiosis cases.46
In one case of pulmonary pythiosis in a 3-year-old
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mare, a pruritic, proliferative, ulcerated lesion consistent
with Pythium spp was surgically excised f rom the
metatarsal region 1 year previously.51 The horse pre-
sented again with a 3-month history of bilateral san-
guineous nasal discharge and coughing during exercise.
A large amount of pleural fluid was observed by radiog-
raphy, and transtracheal wash cultures were positive for
only β-hemolytic Streptococcus spp. At necropsy, multiple
white to pale yellow masses that measured 1 to 20 cm in
diameter were observed throughout the pulmonary
parenchyma. Branching hyphae characteristic of Pythium
spp were cultured from the sequestered tissue.51
Three cases of subcutaneous pythiosis that dissemi-
nated to internal organs (the lungs, liver, and spleen)
were described in Brazilian horses. The subcutaneous
lesions had been treated with radical surgery or im -
muno therapy but had returned or progressed after sev-
eral months of treatment. All the horses eventually
suffered severe weight loss and were euthanized. Granu-
lomatous lesions were found in the lungs and liver at
necropsy in all three horses and in the spleen and lymph
nodes of one horse that had a primary Pythium granu-
loma of the nasal septum. Lesions observed in the inter-
nal organs had the typical infiltration of eosinophils
around necrotic masses (kunker).48
Although there are no reports of antemortem diagno-
sis or treatment of pulmonary pythiosis, immunotherapy
should be recommended. One study showed a 72% suc-
cess rate with the use of immunotherapy that contained
P. insidiosum exoantigens and cytoplasma.47 Immuno-
logic changes observed in cured horses suggest that
immunotherapy may induce a change from a helper T
cell type 2 to a helper T cell type 1 immune response,
which allows the horse’s own immune system to destroy
the Pythium organisms. The P. insidiosum antigens are
injected intramuscularly, and a strong (>10 cm) reaction
at the injection site is associated with a greater likeli-
hood of successful outcome in treating subcutaneous
pythiosis. Disease resolution was also associated with a
shorter duration of clinical signs. Unfortunately, pul-
monary pythiosis in horses is likely to be diagnosed late
in the disease process. Pythiosis immunotherapy has
been used to treat pythiosis in humans and was curative
in a young boy with arterial pythiosis.47 The P. insidio-
sum allergenic extract is available from Pan American
Veterinary Laboratories.a Equine pulmonary pythiosis
could be diagnosed using serology (ELISA, immunodif-
fusion, or Western blot), histopathology using immuno-
histochemical staining, culture, or polymerase chain
reaction of a lung biopsy sample.47,49,52
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1. An association (41 of 49 cases) exists between
invasive pulmonary Aspergillus infection and 
a. hepatitis. d. pleuritis.
b. laminitis. e. nephritis.
c. colitis.
2. Blastomycosis can be identified cytologically by
observing
a. spherical, broad-based budding yeasts with basophilic
protoplasm and unstained, refractile walls that are
often located within multinucleated giant cells.
b. round yeasts with large capsules that do not take up
common stains.
c. round or crescent-shaped organisms with thin, clear
halos and basophilic cytoplasm.
d. all of the above
e. None of the above. Blastomyces spp cannot be readily
identified via cytology alone. A DNA probe or serol-
ogy is required for diagnosis.
3. Which of the following is recognized as a cause
of fungal glossitis?
a. B. dermatitidis d. C. immitis
b. H. capsulatum e. Candida spp
c. Aspergillus spp
4. Which statement regarding P. carinii is incorrect?
a. Culture of P. carinii is impossible. 
b. P. carinii infection can be confirmed using in situ
hybridization on histopathology sections. 
c. P. carinii was originally classified as a protozoan but is
now considered to be a saprophytic fungus.
d. Interstitial pneumonia caused by P. carinii has never
been diagnosed in an immunocompetent horse.
e. all of the above
5. Przewalski’s horses appear to be more suscepti-
ble to infection with 
a. C. immitis. d. C. neoformans.
b. H. capsulatum. e. B. dermatitidis.
c. Conidiobolus coronatus.
6. The treatment of choice for P. carinii infection is
a. amphotericin B.
b. trimethoprim–sulfamethoxazole.
c. itraconazole. 
d. fluconazole.
e. caspofungin.
7. An epidemiologic association between _________
and both the Australian river red gum tree and
bird droppings has been described.
a. C. immitis d. C. neoformans 
b. H. capsulatum e. B. dermatitidis
c. Conidiobolus coronatus
8. Nonpathogenic _________ is/are commonly found
in tracheal aspirate from healthy horses.
a. Alternaria spp d. C.  immitis
b. H. capsulatum e. Candida spp
c. Aspergillus spp
9. The current drug of choice in treating human
aspergillosis is
a. trimethoprim–sulfamethoxazole. 
b. ketoconazole. 
c. amphotericin B.
d. voriconazole.
e. fluconazole. 
10. The prognosis for systemic fungal infections in
horses is
a. excellent.
b. good.
c. guarded.
d. poor.
e. that these conditions are uniformly fatal.
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CASE PRESENTATION
1. What diagnosis would you make based on the above
radiograph?
2. Assuming that the injury is not associated with external
trauma, how is it likely to have occurred?
3. What associated structure may have been injured?
4. If the horse has both problems, which is most likely to
cause persistent lameness?
(See page 274 for answers and explanations.)
Clinical Snapshot presents illustrated case histories and chal-
lenges you to answer the questions posed. This case is part of
the  series of Self-Assessment Colour Review books on multiple
topics from Manson Publishing Ltd., London, available from
Blackwell Publishing Professional. For more information or to
obtain any of the books in the series, call 800-862-6657 or
visit www.blackwellprofessional.com.
Clinical Snapshot
